Neuroleptic malignant syndrome shares features with malignant hyperthermia and is managed by which of the following?

Neuroleptic malignant syndrome shares features with malignant hyperthermia and is managed by which of the following?

• A. Stopping the offending antipsychotic with supportive care and dantrolene
• B. Only stopping the antipsychotic without medication
• C. Routinely continuing haloperidol
• D. Using methylene blue as first-line therapy

Answer: (A)

Neuroleptic malignant syndrome is treated by stopping the offending antipsychotic and providing aggressive supportive care together with dantrolene. The syndrome results from severe dopamine blockade leading to extreme hyperthermia, muscle rigidity, autonomic instability, and metabolic derangements. Halting the causative medication stops the ongoing trigger, while dantrolene helps reduce skeletal muscle contraction and heat production, addressing the core pathophysiology. Supportive measures—cooling, IV fluids, electrolyte and renal monitoring, and careful hemodynamic management—are essential to prevent complications like rhabdomyolysis and organ failure. Simply stopping the drug without additional treatment isn’t sufficient, because the patient still needs active cooling, hydration, and pharmacologic muscle relaxation to control the fever and rigidity. Continuing the antipsychotic would perpetuate the problem and worsen outcomes. Methylene blue is not a standard first-line therapy for this condition and isn’t part of the typical management plan.

Neuroleptic malignant syndrome is treated by stopping the offending antipsychotic and providing aggressive supportive care together with dantrolene. The syndrome results from severe dopamine blockade leading to extreme hyperthermia, muscle rigidity, autonomic instability, and metabolic derangements. Halting the causative medication stops the ongoing trigger, while dantrolene helps reduce skeletal muscle contraction and heat production, addressing the core pathophysiology. Supportive measures—cooling, IV fluids, electrolyte and renal monitoring, and careful hemodynamic management—are essential to prevent complications like rhabdomyolysis and organ failure.

Simply stopping the drug without additional treatment isn’t sufficient, because the patient still needs active cooling, hydration, and pharmacologic muscle relaxation to control the fever and rigidity. Continuing the antipsychotic would perpetuate the problem and worsen outcomes. Methylene blue is not a standard first-line therapy for this condition and isn’t part of the typical management plan.